GlycoMimetics Stockholders Approve Merger with Crescent Biopharma, Creating New Oncology-Focused Entity
Key Insights
GlycoMimetics (search) stockholders approved the proposed merger with Crescent Biopharma on June 5, 2025, along with all related proposals including a 1-for-100 reverse stock split.
The combined company will trade on Nasdaq under the name "Crescent Biopharma, Inc." with ticker symbol "CBIO" starting June 16, 2025, with approximately 14.8 million shares outstanding.
Crescent Biopharma focuses on precision-engineered molecules for solid tumors (search), including lead program CR-001, a tetravalent PD-1 (search) x VEGF (search) bispecific antibody.
GlycoMimetics (search) stockholders have approved a transformative merger with Crescent Biopharma that will create a new oncology-focused biotechnology company, marking a significant consolidation in the precision medicine space. The approval came during a special stockholder meeting held on June 5, 2025, where all merger-related proposals received stockholder support.
Corporate Restructuring and Market Positioning
The merger involves a substantial 1-for-100 reverse stock split that will reduce GlycoMimetics (search)' outstanding shares from approximately 64.5 million to 0.6 million shares. Following the anticipated merger closing, the combined entity will begin trading on The Nasdaq Capital Market on June 16, 2025, under the new corporate identity "Crescent Biopharma, Inc." with ticker symbol "CBIO."
The combined company's capital structure will consist of approximately 14.8 million shares outstanding, or 25.3 million shares on a fully-diluted basis. GlycoMimetics (search) stockholders also approved an increase in authorized common stock from 150 million to 175 million shares to facilitate the transaction.
Strategic Pipeline Combination
The merger brings together complementary therapeutic approaches targeting cancer treatment. GlycoMimetics (search) contributed its late clinical-stage glycobiology platform, which was previously focused on developing therapies for cancers (search) including acute myeloid leukemia (search) (AML (search)) and inflammatory diseases (search). The company's scientific approach centered on understanding carbohydrate-mediated cell recognition and developing small molecule glycomimetics that alter these recognition processes in disease states.
Crescent Biopharma adds a pipeline of three precision-engineered programs targeting solid tumors (search). The company's lead program, CR-001, represents a tetravalent PD-1 (search) x VEGF (search) bispecific antibody designed to harness validated biology for potentially best-in-class therapeutic outcomes. Additionally, Crescent is advancing CR-002 and CR-003, which are antibody drug conjugates featuring topoisomerase (search) inhibitor payloads for undisclosed targets.
Financial and Operational Details
The reverse stock split will not affect the number of authorized shares, and proportionate adjustments will be made to exercise prices and share counts for outstanding equity awards. Stockholders who would receive fractional shares will instead receive cash payments calculated based on the closing price on June 12, 2025, adjusted for the reverse stock split ratio.
The transaction represents a strategic pivot for GlycoMimetics (search), which had been developing transformative therapies for diseases with high unmet medical need through its specialized chemistry platform. The merger with Crescent creates a focused oncology entity with multiple clinical programs targeting different aspects of cancer biology.
Market Implications
The combined entity positions itself in the competitive precision oncology market with a diversified approach spanning glycobiology-based therapies and precision-engineered bispecific antibodies and antibody drug conjugates. The merger reflects ongoing consolidation trends in biotechnology as companies seek to combine complementary platforms and pipelines to enhance their competitive positioning and development capabilities.